Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TCP 25

X
Drug Profile

TCP 25

Alternative Names: BioC; BioC gel; TCP-25

Latest Information Update: 24 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lund University
  • Developer Xinnate
  • Class Anti-inflammatories; Antibacterials; Antifungals; Peptides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epidermolysis bullosa; Varicose ulcer
  • Preclinical Bacterial infections; Mycoses

Most Recent Events

  • 19 Sep 2024 Xinnate plans a phase II trial for Epidermolysis bullosa (In children, In adolescents, In adults, In elderly) in Sweden (Topical, Gel) in March 2025 (NCT06594393)
  • 21 Sep 2023 Preclinical trials in Mycoses in Sweden (Transdermal) (Xinnate website, Sep 2023)
  • 07 Dec 2022 Xinnate AB in collaboration with Region Skane completes enrollment in a phase I trial for Epidermolysis bullosa dystrophica (In volunteers) in Sweden (Transdermal)(NCT05378997) (EudraCT2021-004728-14)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top